Immune modulation therapy-ischaemia/reperfusion injury - Vasogen
Alternative Names: VAS 971Latest Information Update: 05 Dec 2003
Price :
$50 *
At a glance
- Originator Vasogen
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury
Most Recent Events
- 05 Dec 2003 No development reported - Phase-I for Reperfusion injury in USA (Parenteral)
- 05 Dec 2003 No development reported - Preclinical for Reperfusion injury in Canada (Parenteral)
- 28 Feb 2000 VAS 971 is available for licensing (http://www.vasogen.com)